Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic anti-EGFR CAR/HLA-A*02-gated inhibitory receptor-expressing T lymphocytes A2B395

A preparation of allogeneic T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the epidermal growth factor receptor (EGFR; HER1; ErbB1), and a leukocyte immunoglobulin-like receptor 1 (LIR-1)-based inhibitory receptor specific for human leukocyte antigen (HLA)-A*02 (HLA-A*02), with potential immunomodulating and antineoplastic activities. Upon administration, the allogeneic anti-EGFR CAR/HLA-A*02-gated inhibitory receptor-expressing T lymphocytes A2B395 target and bind to EGFR-expressing tumor cells, thereby killing EGFR-expressing tumor cells that have loss of heterozygosity (LOH) for HLA-A*02 protein. The inhibitory receptor specific for HLA-A*02 acts as a self-regulated safety switch that blocks the killing of HLA-A*02-positive EGFR-expressing normal, healthy cells. This may also protect the normal, healthy cells from graft versus host disease (GvHD) resulting from the administration of the allogeneic T cells. HLA-A*02 is expressed on normal cells but not on tumor cells due to LOH. EGFR, overexpressed by a variety of cancers, plays a key role in tumor cell proliferation and survival.
Synonym:allogeneic anti-EGFR CAR/HLA-A*02-gated inhibitory receptor-expressing T cells A2B395
allogeneic anti-EGFR logic-gated Tmod CAR-T cells A2B395
Search NCI's Drug Dictionary